
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Therapeutics is expected to perform well in the future due to its pioneering program, detalimogene voraplasmid, for patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program has shown competitive efficacy and potential best-in-class tolerability in the ongoing LEGEND Phase 2 trial, with a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients. Additionally, enGene's Dually Derivatized Oligochitosan (DDX) platform boasts ease of use and no special handling or storage requirements, making it a potential first-choice treatment for community urologists who treat the majority of NMIBC patients. This could lead to a significant increase in the company's valuation and future success in addressing other malignancies.
Bears say
enGene Therapeutics is facing multiple challenges as it moves towards the commercialization of its lead product candidate, detalimogene, which is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial for bladder cancer. While bladder cancer is a high clinical burden disease with a significant unmet need for effective treatments, enGene's current financials and lack of approved products put it at a disadvantage compared to its competitors in the gene therapy space. Furthermore, the company's success will heavily depend on the success of the ongoing trial and the timely approval and launch of detalimogene, which may face challenges in a competitive market with multiple approved options.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares